OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results
- OPKO Health's collaboration agreement with Merck for MDX-2201 could bring in up to $872.5 million in milestone payments and royalties on global net sales. Sales of NGENLA® by Pfizer are underway in 17 countries, with plans to launch in all priority international markets by year-end. BioReference Health's new dual-stain triage test enhances cervical cancer screenings, providing valuable information for healthcare providers.
- Diagnostics revenue decreased in Q1 2023 due to lower COVID-19 testing volume. Consolidated total revenues decreased compared to Q1 2022. OPKO Health reported a net loss of $18.3 million in Q1 2023. Cash and cash equivalents were $110.8 million as of March 31, 2023.
Conference call begins at 4:30 p.m. Eastern time today
MIAMI, May 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023.
First quarter business highlights include the following:
- OPKO Health’s ModeX Therapeutics, Inc. (ModeX) entered into an exclusive worldwide license and collaboration agreement with Merck to develop MDX-2201 for Epstein-Barr virus. Under the terms of the agreement, OPKO received a
$50.0 million upfront payment and is eligible to receive up to an additional$872.5 million upon the achievement of prespecified development and commercial milestones. In addition, upon commercial launch of MDX-2201, OPKO is eligible to receive royalties on global net sales. Merck will be responsible for clinical and regulatory costs and activities, as well as product commercialization. - Sales are underway by Pfizer for NGENLA® (somatrogon) in 17 countries including Japan, Germany and the United Kingdom; NGENLA® has been approved in 41 countries and Pfizer continues to work with the FDA to obtain approval in the U.S. NGENLA treats pediatric patients with decreased growth due to insufficient growth hormone and reduces the injection frequency from once daily to once weekly. NGENLA is the first once-weekly product approved for the treatment of pediatric growth hormone deficiency in Japan, Canada, Australia, the United Kingdom, Taiwan, United Arab Emirates and Brazil, and was recently approved in Korea and Turkey. Its European Union marketing authorization is valid in all EU Member States, as well as in Iceland, Norway and Liechtenstein. Pfizer expects to launch in all priority international markets by year-end.
- BioReference Health is one of the first commercial laboratories to offer a dual-stain triage test to enhance cervical cancer screenings. The CINtec® PLUS Cytology test from Roche Diagnostics is the only approved dual-stain triage test for patients who have a high-risk human papillomavirus result. The dual-stain biomarker test allows healthcare providers to assess a patient’s risk for cervical pre-cancer more accurately and quickly. BioReference is driving innovation to its portfolio with new tests to provide valuable information for healthcare providers and their patients.
First Quarter Financial Results
- Pharmaceuticals: Revenue from products in the first quarter of 2023 increased to
$40.4 million from$36.6 million in the first quarter of 2022, driven by sales in our international operating companies and an increase in sales of Rayaldee to$6.6 million from$5.1 million in the prior-year period. Revenue from the transfer of intellectual property was$64.8 million in the first quarter of 2023 compared with$6.0 million in the 2022 period. The increase in revenue from the transfer of intellectual property reflects a$50.0 million upfront payment from Merck, a$7.0 million milestone payment from Vifor Fresenius Medical Care Renal Pharma triggered by the German price approval related to Rayaldee and a$2.5 million milestone payment from Nicoya Therapeutics related to the submission of its investigational new drug application to China's Center for Drug Evaluation for Rayaldee. Total costs and expenses were$86.3 million in the first quarter of 2023, up from$60.7 million in the prior-year period. The increase was mainly due to a$12.5 million payment to Sanofi that accrued under a Sanofi In-License Agreement between ModeX and Sanofi, and research expenses at ModeX, which was acquired in May 2022. Operating income was$19.0 million in the first quarter of 2023, compared with an operating loss of$18.1 million in the first quarter of 2022. - Diagnostics: Revenue from services in the first quarter of 2023 was
$132.4 million compared with$286.6 million in the prior-year period. Revenue decreased due to lower COVID-19 testing volume. BioReference processed approximately 68,000 COVID-19 PCR tests in the first quarter of 2023, representing4.8% of total volume, versus 2.0 million tests in the first quarter of 2022, representing46.9% of total volume. Furthermore, revenue decreased by$36.1 million due to the sale of GeneDx in April 2022. Total costs and expenses were$172.4 million in the first quarter of 2023 compared with$330.1 million in the first quarter of 2022, resulting in an operating loss of$40.0 million compared with an operating loss of$43.5 million in the 2022 period, which included approximately$16.0 million from GeneDx. BioReference is implementing significant cost-reduction initiatives as it strives to return to profitability. - Consolidated: Consolidated total revenues for the first quarter of 2023 were
$237.6 million compared with$329.2 million for the comparable period of 2022. Operating loss for the first quarter of 2023 decreased$41.8 million to$30.6 million from$72.4 million for the 2022 quarter. Net loss for the first quarter of 2023 was$18.3 million , or$0.02 per share, compared with a net loss of$55.4 million , or$0.08 per share, for the 2022 quarter. Net loss for the first quarter of 2023 included non-cash income of$8.3 million due to an increase in the fair value of OPKO’s GeneDx Holdings (formerly Sema4 Holdings Corp) investment and non-cash income of$8.5 million as a result of GeneDx Holdings achieving specific revenue targets for the 2022 fiscal year. - Cash and cash equivalents: Cash and cash equivalents were
$110.8 million as of March 31, 2023, which does not include the$50 million upfront payment from Merck that was received in April 2023.
Conference Call and Webcast Information
OPKO’s senior management will provide a business update, discuss first quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time. Participants are encouraged to pre-register for the conference call here. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.
A telephone replay will be available until May 10, 2023 by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 4576780. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, whether our products will launch in all the territories in which they have been approved for sale, the timing of such launches, the ability to get beneficial pricing approvals, our product development efforts and the expected benefits of our products, whether the relationship with our business partners will be successful, whether our business partners will be able to commercialize our products and successfully utilize our technologies, our ability to market and sell any of our products in development, whether BioReference’s cost-cutting initiatives and attempts at returning to its core business will be successful, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission, as well as the continuation and success of our relationship with our commercial partners, liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Contacts:
LHA Investor Relations
Yvonne Briggs, 310-691-7100
ybriggs@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
—Tables to Follow—
| OPKO Health, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in millions) Unaudited | |||||||
| As of | |||||||
| March 31, 2023 | December 31, 2022 | ||||||
| Assets: | |||||||
| Cash and cash equivalents | $ | 110.8 | $ | 153.2 | |||
| Other current assets | 295.6 | 241.3 | |||||
| Total current assets | 406.4 | 394.5 | |||||
| In-process research and development and goodwill | 792.4 | 790.9 | |||||
| Other assets | 970.8 | 981.9 | |||||
| Total Assets | $ | 2,169.6 | $ | 2,167.3 | |||
| Liabilities and Equity: | |||||||
| Accounts Payable | $ | 80.5 | $ | 67.0 | |||
| Accrued expenses | 106.0 | 98.3 | |||||
| Current portion of convertible notes | 0.0 | 3.1 | |||||
| Other current liabilities | 35.9 | 45.1 | |||||
| Total current liabilities | 222.4 | 213.5 | |||||
| Long term portion of convertible notes | 211.3 | 210.4 | |||||
| Deferred tax liabilities, net | 129.7 | 126.4 | |||||
| Other long-term liabilities, principally contract liabilities, leases, contingent consideration and lines of credit | 54.4 | 55.4 | |||||
| Total Liabilities | 617.8 | 605.7 | |||||
| Equity | 1,551.8 | 1,561.6 | |||||
| Total Liabilities and Equity | $ | 2,169.6 | $ | 2,167.3 | |||
| OPKO Health, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in millions, except share and per share data) Unaudited | ||||||||
| For the three months ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Revenues | ||||||||
| Revenue from services | $ | 132.4 | $ | 286.6 | ||||
| Revenue from products | 40.4 | 36.6 | ||||||
| Revenue from transfer of intellectual property | 64.8 | 6.0 | ||||||
| Total revenues | 237.6 | 329.2 | ||||||
| Costs and expenses | ||||||||
| Cost of revenues | 138.3 | 243.9 | ||||||
| Selling, general and administrative | 75.7 | 117.5 | ||||||
| Research and development | 32.6 | 18.3 | ||||||
| Contingent consideration | 0.1 | (0.1 | ) | |||||
| Amortization of intangible assets | 21.5 | 22.0 | ||||||
| Total costs and expenses | 268.2 | 401.6 | ||||||
| Operating loss | (30.6 | ) | (72.4 | ) | ||||
| Other income and (expense), net | 13.6 | (4.2 | ) | |||||
| Loss before income taxes and investment losses | (17.0 | ) | (76.7 | ) | ||||
| Income tax benefit (provision) | (1.2 | ) | 21.3 | |||||
| Net loss before investment losses | (18.2 | ) | (55.3 | ) | ||||
| Loss from investments in investees | (0.1 | ) | (0.1 | ) | ||||
| Net loss | $ | (18.3 | ) | $ | (55.4 | ) | ||
| Loss per share, basic and diluted | $ | (0.02 | ) | $ | (0.08 | ) | ||
Weighted average common shares outstanding, basic and diluted | 751,506,257 | 660,302,426 | ||||||
FAQ
What are the business highlights for OPKO Health in Q1 2023?
How did revenue perform in OPKO Health's Pharmaceuticals segment in Q1 2023?
What caused the decrease in revenue in OPKO Health's Diagnostics segment in Q1 2023?
What was OPKO Health's net loss in Q1 2023?
What is the cash and cash equivalents for OPKO Health as of March 31, 2023?
